81 results match your criteria medtronic sprint


In vitro Modeling Accurately Predicts Cardiac Lead Fracture at 10 Years.

Heart Rhythm 2021 May 13. Epub 2021 May 13.

Vanderbilt Heart and Vascular Institute, Nashville, TN, USA.

Background: Development of a cardiac lead fracture model has the potential to differentiate well performing lead designs from poor performing ones and could aid in future lead development.

Objective: To demonstrate a predictive model for lead fracture and validate the results generated by the model by comparing them to observed 10-year implantable cardioverter defibrillator lead fracture free survival.

Methods: The model presented here uses a combination of in vivo patient data, in vitro conductor fatigue test data and statistical simulation to predict the fracture-free survival of cardiac leads. Read More

View Article and Full-Text PDF

The American Society of Pain and Neuroscience (ASPN) Practical Guidelines to Study Design and Scientific Manuscript Preparation in Neuromodulation.

J Pain Res 2021 16;14:1027-1041. Epub 2021 Apr 16.

The Spine and Nerve Center of the Virginias, Charleston, WV, USA.

Background: Healthcare clinical and even policy decisions are progressively made based on research-based evidence. The process by which the appropriate trials are developed and well-written manuscripts by means of evidence-based medicine recommendations has resulted in unprecedented necessity in evidence-based medicine in neuromodulation.

Methods: The essential considerations in the planning of neuromodulation research are discussed in the light of available scientific literature as well as the authors' scientific expertise regarding research study design and scientific manuscript preparation. Read More

View Article and Full-Text PDF

Thoracic paravertebral block is a promising option for analgesia for subcutaneous implantable cardioverter defibrillator implantation surgery - A retrospective study.

J Clin Anesth 2020 Nov 1;66:109918. Epub 2020 Jun 1.

Department of Anesthesiology, Division of Interventional Pain Medicine, Temple University Health System, United States of America. Electronic address:

View Article and Full-Text PDF
November 2020

Comparison of the performance of implantable cardioverter-defibrillator leads among manufacturers.

J Interv Card Electrophysiol 2020 Aug 5;58(2):133-139. Epub 2019 Nov 5.

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Background: Leads are often considered the weakest link in implantable cardioverter-defibrillator (ICD) systems, and lead dysfunction is a major concern for ICD recipients. The aim of this study was to compare the lead performance from three different manufacturers.

Methods: We retrospectively reviewed consecutive patients who underwent ICD system implantation at Chiba University Hospital, Japan, between March 2008 and September 2017. Read More

View Article and Full-Text PDF

The Medtronic Sprint Fidelis® lead history revisited-Extended follow-up of passive leads.

Pacing Clin Electrophysiol 2019 12 6;42(12):1529-1533. Epub 2019 Nov 6.

Department of Cardiology, University Hospital of Basel, Basel, Switzerland.

Background: Due to high failure rates, Medtronic withdrew the Sprint Fidelis lead (SFL) from the market. Passive fixation lead models exhibited better survival than active models, but most studies have limited follow-up. Aim of this study was to give insights into passive lead survival with a follow-up of 10 years. Read More

View Article and Full-Text PDF
December 2019

Performance of the Linox implantable cardioverter defibrillator leads: A single-center experience.

Pacing Clin Electrophysiol 2019 12 30;42(12):1524-1528. Epub 2019 Oct 30.

Davidai Arrhythmia Center, Levaiev Heart Institute, Sheba Medical Center, Tel Hashomer, and Sackler School of medicine, Tel Aviv University, Tel Aviv, Israel.

Background: An early failure of Biotronik Linox implantable cardioverter defibrillator (ICD) leads has been reported from several centers.

Aim: To compare the performance of Linox ICD leads with different other ICD leads as a report of the Sheba Medical Center experience.

Methods: All patients who had implantation of Linox ICD leads between 2007 and 2016 were included in this study. Read More

View Article and Full-Text PDF
December 2019

A Strategy of Lead Abandonment in a Large Cohort of Patients With Sprint Fidelis Leads.

JACC Clin Electrophysiol 2019 09 28;5(9):1059-1067. Epub 2019 Aug 28.

Arrhythmia Service, Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada. Electronic address:

Objectives: This study sought to examine outcomes of our approach to managing a large cohort of patients with Sprint Fidelis (Medtronic, Minneapolis, Minnesota) leads.

Background: The optimal management approach for patients with leads under advisory is unknown. Concerns regarding the risk of device infection and complications associated with delaying lead extraction have recently been suggested to argue against abandoning leads under advisory. Read More

View Article and Full-Text PDF
September 2019

Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation.

BMJ Open 2019 03 23;9(3):e025936. Epub 2019 Mar 23.

Department of Health Policy and Management, Yale University School of Public Health, New Haven, Connecticut, USA.

Objectives: To collate and systematically characterise the methods, results and clinical performance of the clinical risk prediction submissions to the Systolic Blood Pressure Intervention Trial (SPRINT) Data Analysis Challenge.

Design: Cross-sectional evaluation.

Data Sources: SPRINT Challenge online submission website. Read More

View Article and Full-Text PDF

Comparison of lead failure manifestation of Biotronik Linox with St. Jude Medical Riata and Medtronic Sprint Fidelis lead.

J Interv Card Electrophysiol 2019 Mar 23;54(2):161-170. Epub 2018 Nov 23.

Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.

Purpose: To compare lead failure manifestation and lead performance of the Biotronik Linox/Sorin Vigila defibrillator lead (Linox group) with the St. Jude Medical Riata/Riata ST (Riata group) and Medtronic Sprint Fidelis defibrillator leads (Fidelis group).

Methods: We assessed the performance of all aforementioned leads implanted at our center and investigated the manifestation of lead failures. Read More

View Article and Full-Text PDF

Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population.

BMJ Open 2018 07 23;8(7):e021685. Epub 2018 Jul 23.

Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut, USA.

Objectives: To understand the discrepancy between the published 10-year cardiovascular risk and 10-year cardiovascular risk generated from raw data using the Framingham Risk Score for participants in the Systolic Blood Pressure Intervention Trial (SPRINT).

Design: Secondary analysis of SPRINT data published in () and made available to researchers in late 2016.

Setting: SPRINT clinical trial sites. Read More

View Article and Full-Text PDF

Analysis of early failure of Biotronik Linox Smart implantable cardioverter-defibrillator leads: A comparative study of three defibrillator leads.

Pacing Clin Electrophysiol 2018 09 11;41(9):1165-1170. Epub 2018 Jul 11.

Arrhythmia Unit, Cardiology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

Background And Objectives: Early failure of Biotronik Linox and Linox Smart leads (Biotronik, Berlin, Germany) has been reported in numerous recent publications. The aim of this study was to assess the performance of this lead compared with that of two other contemporary leads.

Methods: We conducted an ambispective study of all consecutive first implantations of defibrillator leads carried out in our center: Endotak (model 148, 158, Boston Scientific, Marlborough, MA, USA) (n = 173), Sprint Quattro (model 6644, 6947, Medtronic, Dublin, Ireland) (n = 145), and Linox Smart (Biotronik, model SD 65/16) (n = 120). Read More

View Article and Full-Text PDF
September 2018

Clinical performance of different DF-4 implantable cardioverter defibrillator leads.

Pacing Clin Electrophysiol 2018 Jun 1. Epub 2018 Jun 1.

Department of Cardiology, Institut universitaire de cardiologie et pneumologie de Québec, Quebec, QC, Canada.

Introduction: Implantable cardioverter-defibrillator (ICD) DF-4 connectors have been introduced to facilitate defibrillator lead connection and to reduce the size of device header. There are limited data regarding the overall performance of those leads and no comparison between different ICD DF-4 leads.

Methods: This is a cohort study of consecutive patients implanted with ICD DF-4 lead system at one University Centre between October 2010 and February 2015. Read More

View Article and Full-Text PDF

Mechanisms of Lead Failure by Recall Status and Manufacturer: Results From the Pacemaker and Implantable Defibrillator Leads Survival Study ("PAIDLESS").

J Invasive Cardiol 2018 Apr;30(4):147-151

Department of Medicine, NYU Winthrop Hospital, 212 Jericho Turnpike, Mineola, NY 11501 USA.

Objectives: The aim of this study was to determine the differences in lead failure mechanisms across the major United States implantable defibrillator lead manufacturers (Boston Scientific, Medtronic, and St. Jude Medical), between all non-recalled and recalled leads, and between two recalled lead families (Medtronic Sprint Fidelis and the St. Jude Medical Riata and Riata ST). Read More

View Article and Full-Text PDF

Comparison of longevity and clinical outcomes of implantable cardioverter-defibrillator leads among manufacturers.

Heart Rhythm 2017 10 11;14(10):1496-1503. Epub 2017 May 11.

Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Background: An early failure of the Biotronik Linox S/SD implantable cardioverter-defibrillator (ICD) lead has been reported. We have also experienced several cases with early failure of Linox leads.

Objective: Our aim was to assess the longevity of Linox S/SD (Biotronik, Berlin, Germany) compared with Sprint Fidelis (Medtronic, Minneapolis, MN), Sprint Quattro (Medtronic), and Endotak Reliance (Boston Scientific, Natick, Massachusetts) leads. Read More

View Article and Full-Text PDF
October 2017

The Impact of Inappropriate Implantable Cardiac Defibrillator Shocks on Cardiovascular Morbidity and Mortality.

Pacing Clin Electrophysiol 2016 Aug 7;39(8):858-62. Epub 2016 Jun 7.

Division of Cardiac Electrophysiology, The Ohio State University, Columbus, Ohio.

Background: The impact of inappropriate implantable cardiac defibrillator (ICD) shocks on cardiac outcomes is controversial. Shocks due to lead noise are unique in that they are not an outcome of worsening rhythm status. In this study, we compared the outcome of patients with and without inappropriate shocks who underwent Sprint Fidelis lead (Medtronic Inc. Read More

View Article and Full-Text PDF

Impact of generator replacement on the risk of Fidelis lead fracture.

Heart Rhythm 2016 08 3;13(8):1618-23. Epub 2016 May 3.

Tufts Medical Center, Boston, Massachusetts.

Background: A dilemma arises about the merits of conservative management vs lead replacement and/or extraction when patients with a Medtronic Sprint Fidelis lead undergo generator replacement. Conflicting reports suggest that the fracture rate may increase after generator change.

Objective: The purpose of this study was to investigate the effect of generator replacement on Fidelis lead performance. Read More

View Article and Full-Text PDF

Small-Caliber Lead Failure After Generator Exchange.

J Cardiovasc Electrophysiol 2016 07 31;27(7):846-50. Epub 2016 May 31.

University Hospital of Burgos, Spain.

Introduction And Objectives: The Sprint Fidelis defibrillator lead (Medtronic) was recalled in 2007 due to an increased risk of failure. The generator exchange (GE) procedure has been associated with the development of Fidelis lead dysfunction. The aim of this study was to compare the rate of dysfunction between Sprint Fidelis and other defibrillator leads during the first year after GE. Read More

View Article and Full-Text PDF

Failure rate and conductor externalization in the Biotronik Linox/Sorin Vigila implantable cardioverter-defibrillator lead.

Heart Rhythm 2016 05 29;13(5):1075-1082. Epub 2015 Dec 29.

Department of Cardiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. Electronic address:

Background: We observed a case of conductor externalization in a Biotronik Linox lead.

Objective: The purpose of this study was to investigate lead performance of the Linox lead and the identical Sorin Vigila lead and prevalence of conductor externalization.

Methods: We compared lead performance of all Linox and Vigila leads implanted at our center (BL group; n = 93) with that of all Boston Scientific Endotak Reliance leads (ER group; n = 190) and Medtronic Sprint Quattro leads (SQ group; n = 202) implanted during the same period. Read More

View Article and Full-Text PDF

Transvenous Implantable Cardioverter-Defibrillator (ICD) Lead Performance: A Meta-Analysis of Observational Studies.

J Am Heart Assoc 2015 Oct 30;4(11). Epub 2015 Oct 30.

The Heart Hospital, University College of London Hospitals NHS Trust, London, United Kingdom (R.P., G.G.B., P.D.L.) University College of London, United Kingdom (A.I., P.D.L.) Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom (R.P., P.D.L.).

Background: Despite the widespread use of implantable cardioverter-defibrillators (ICDs) in clinical practice, concerns exist regarding ICD lead durability. The performance of specific lead designs and factors determining this in large populations need clarification.

Methods And Results: The Medline, Embase, and Cochrane Collaboration databases were searched for studies including ≥2 of the most commonly implanted leads. Read More

View Article and Full-Text PDF
October 2015

Sudden and Fatal Malfunction of a Durata Defibrillator Lead due to External Insulation Failure.

Pacing Clin Electrophysiol 2016 Jan 17;39(1):101-4. Epub 2015 Sep 17.

Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia.

Defibrillator lead malfunction can be a disastrous complication, leading to loss of protection from sudden cardiac death in a high-risk patient population. Recognition of lead-specific risk for failure can assist in development of focused screening or surveillance, as in the case of the Riata lead (St. Jude Medical, St. Read More

View Article and Full-Text PDF
January 2016

[ICD leads].

Herzschrittmacherther Elektrophysiol 2015 Jun;26(2):94-104

Klinik für Innere Medizin - Kardiologie, Diabetologie & Nephrologie, Evangelisches Krankenhaus Bielefeld, Burgsteig 13, 33617, Bielefeld, Deutschland,

Implantable cardioverter-defibrillator (ICD) leads have to fulfill particular requirements: safe pacing and sensing, detection, and termination of ventricular tachyarrhythmias, if necessary by (multiple) high-energy shocks. At the same time, their implantation has to be simple, they need to provide excellent long-term stability and they must be completely and safely extractable. Numerous technical developments have enabled currently available ICD leads to fulfill these expectations to a high extent. Read More

View Article and Full-Text PDF

A Comparative Study of Defibrillator Leads at a Large-Volume Implanting Hospital: Results From the Pacemaker and Implantable Defibrillator Leads Survival Study ("PAIDLESS").

J Invasive Cardiol 2015 Jun;27(6):292-300

Winthrop University Hospital, 120 Mineola Boulevard, Suite 500, Mineola, NY 11501 USA.

Objectives: The purpose of the study was to examine survival in the implantable defibrillator subset of implanted leads at a large-volume implanting hospital.

Background: Implantable lead survival has been the subject of many multicenter studies over the past decade. Fewer large implanting volume single-hospital studies have examined defibrillator lead failure as it relates to patient survival and lead construction. Read More

View Article and Full-Text PDF

Transvenous implantable cardioverter-defibrillator lead reliability: implications for postmarket surveillance.

J Am Heart Assoc 2015 May 29;4(6):e001672. Epub 2015 May 29.

Minneapolis Heart Institute Foundation, Minneapolis, MN (D.M.G., L.K.R., R.G.H.).

Background: As implantable cardioverter-defibrillator technology evolves, clinicians and patients need reliable performance data on current transvenous implantable cardioverter-defibrillator systems. In addition, real-world reliability data could inform postmarket surveillance strategies directed by regulators and manufacturers.

Methods And Results: We evaluated Medtronic Sprint Quattro, Boston Scientific Endotak, and St Jude Medical Durata and Riata ST Optim leads implanted by participating center physicians between January 1, 2006 and September 1, 2012. Read More

View Article and Full-Text PDF

Managing patients with advisory defibrillator leads: what can we learn from published data?

Neth Heart J 2015 Apr;23(4):199-204

Department of Cardiology, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands,

Defibrillator lead advisories stir a lot of emotions, both with patients and physicians, and this may influence lead management. We reviewed the literature for a more evidence-based approach to this issue.From the complications of two of the current advisory leads, the Medtronic Sprint Fidelis and St. Read More

View Article and Full-Text PDF

Very late follow-up of a passive defibrillator lead under recall: do failure rates increase during long-term observation.

Pacing Clin Electrophysiol 2015 Mar 20;38(3):306-10. Epub 2015 Jan 20.

University Hospital of Basel, Basel, Switzerland.

Background: The Medtronic Sprint Fidelis lead (SFL; Medtronic Inc., Minneapolis, MN, USA) has a significantly impaired long-term survival, and active fixation leads fare worse than passive leads. The goal of this study was to present data of a series of passive SFL only with very long mean follow-up of more than 6 years. Read More

View Article and Full-Text PDF

Long-term outcome of sirolimus-eluting and zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a Danish organization for randomized trials on clinical outcome III substudy).

Am J Cardiol 2015 Feb 11;115(3):298-302. Epub 2014 Nov 11.

Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. Electronic address:

We compared 5-year clinical outcomes in diabetic and nondiabetic patients treated with Endeavor zotarolimus-eluting stents (ZESs; Endeavor Sprint, Medtronic, Santa Rosa, California) or Cypher sirolimus-eluting stents (SESs; Cordis, Johnson & Johnson, Warren, New Jersey) coronary implantation. We randomized 2,332 patients to either ZESs (n = 1,162, n = 169 diabetic patients) or SESs (n = 1,170, n = 168 diabetic patients) stratified according to presence or absence of diabetes mellitus. End points included major adverse cardiac event (MACE), a composite of cardiac death, myocardial infarction, target vessel revascularization (TVR), and definite stent thrombosis. Read More

View Article and Full-Text PDF
February 2015

Failure rates of single- versus dual-coil nonrecalled sprint quattro defibrillator leads.

Am J Cardiol 2015 Jan 30;115(2):202-5. Epub 2014 Oct 30.

Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address:

Electrical failure is more common in single-coil compared with dual-coil implantable cardioverter defibrillator (ICD) leads in the case of the recalled Riata lead. Single-coil leads are however favored in most patients given their lower risk of extraction. We therefore evaluated the failure-free survival of single- versus dual-coil ICD leads not included in Food and Drug Administration recalls. Read More

View Article and Full-Text PDF
January 2015

Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.

Lancet 2014 Jun 14;383(9934):2047-2056. Epub 2014 Mar 14.

Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark.

Background: In head-to-head comparisons of coronary drug-eluting stents, the primary endpoint is traditionally assessed after 9-12 months. However, the optimum timepoint for this assessment remains unclear. In this study, we assessed clinical outcomes at up to 5 years' follow-up in patients who received two different types of drug-eluting stents. Read More

View Article and Full-Text PDF

Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).

JACC Cardiovasc Interv 2014 Jan 11;7(1):20-8. Epub 2013 Dec 11.

Medical Statistics Unit, University of Brescia, Brescia, Italy.

Objectives: This study sought to assess device-specific outcomes after implantation of bare-metal stents (BMS), zotarolimus-eluting Endeavor Sprint stents (ZES-S), paclitaxel-eluting stents (PES), or everolimus-eluting stents (EES) (Medtronic Cardiovascular, Santa Rosa, California) in all-comer patients undergoing percutaneous coronary intervention.

Background: Few studies have directly compared second-generation drug-eluting stents with each other or with BMS.

Methods: We randomized 2,013 patients to BMS, ZES-S, PES, or EES implantation. Read More

View Article and Full-Text PDF
January 2014

Implantable cardioverter-defibrillator lead failure in children and young adults: a matter of lead diameter or lead design?

J Am Coll Cardiol 2014 Jan 16;63(2):133-40. Epub 2013 Oct 16.

Division of Cardiology, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Objectives: This study aimed to investigate the impact of lead diameter and design on implantable cardioverter-defibrillator (ICD) lead survival in children and young adults.

Background: Recent reports have called attention to high rates of lead failure in adults with small-diameter ICD leads, but data in the pediatric population is limited.

Methods: We reviewed lead performance in consecutive subjects ≤30 years with transvenous right ventricular ICD leads implanted at our center between January 1995 and October 2011. Read More

View Article and Full-Text PDF
January 2014